Neurogene (NGNE) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- -$1.37
- Surprise
- —
- Score today
- 5.4/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Canaccord Genuity Maintains Buy on Neurogene, Lowers Price Target to $166 — benzinga, 2026-08-12
- Guggenheim Maintains Buy on Neurogene, Raises Price Target to $81 — benzinga, 2026-08-12
- HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $65 — benzinga, 2026-08-12
Where TrendMatrix's rating stands now
TrendMatrix currently rates NGNE Sell at 5.4/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-12.
What argues against it
- Concentration risk — Pipeline: NGN-401 (Rett syndrome)
- Quality below floor (1.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $31.14
- Price target
- $67.75
- Stop
- $28.96
- Upside to target
- +117.6%
- Reward-to-risk
- 7.8:1
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
NGNE at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $608.7M
- P/E (fwd)
- -5.3
- 52-week range
- $15.93–$43.66
- Off 52-week high
- 28.7%
- RSI (14)
- 61
- Volume vs avg
- 0.03×
- Score today
- 5.4/10